The Indian government has initiated a safety review of popular weight-loss drugs, particularly those in the GLP-1 category, following a significant rise in demand. The Indian Pharmacopoeia Commission (IPC) is responsible for compiling reports on adverse events associated with these medications. This move is prompted by the expiration of the patent for semaglutide, which is expected to lead to a surge in affordable generic versions. Market research firm PharmaTrac predicts that the obesity drug segment could grow from ₹1,500 crore (approximately $180 million USD) to ₹8,000 crore (approximately $960 million USD) by 2030. The Drug Consultative Committee (DCC) has proposed enhanced regulatory oversight to combat surrogate advertising of prescription-only medicines, particularly concerning GLP-1 receptor agonists. The DCC's strategy includes close monitoring by state and Union Territory drug controllers to ensure compliance with ethical marketing practices and risk management obligations. The IPC will provide monthly or bi-monthly reviews to strengthen post-marketing surveillance, addressing concerns that individuals may pursue these drugs without adequate medical guidance.